DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study of Memantine to Treat Huntington's Disease

Information source: University of California, San Diego
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Huntington's Disease

Intervention: Memantine (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: University of California, San Diego

Overall contact:
Jody Corey-Bloom, MD, PhD, Phone: 858-642-3470, Email: jcoreybl@vapop.ucsd.edu


To determine if memantine in doses of 10 mg BID affects memory, cognition, and behavior in patients with Huntington's disease (HD).

Clinical Details

Official title: A Pilot Study of Memantine for Cognitive and Behavioral Dysfunction in Huntington's Disease"

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: sensitive neuropsychological battery

Secondary outcome: behavioral and functional measures at three and six months of treatment

Detailed description: Results of several published clinical trials suggest that memantine has a beneficial effect in dementing conditions, such as Alzheimer's disease; however, the effects of memantine on cognitive and behavioral function in HD are unknown. Our hypotheses are that HD patients who are administered memantine will show improved performance on psychometric tests of memory and executive functions in addition to behavior and that patients treated with memantine will show more improvement after six months than after three months of treatment.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Men or women aged 18 or older.

- Diagnosis of HD with current complaints of memory or concentration difficulties.

- Dementia Rating Scale score of <129, to ensure that patients have sufficient

cognitive impairment.

- Adequate visual and auditory acuity to allow neuropsychological testing.

- Good general health with no additional diseases expected to interfere with the study.

- Patient is not institutionalized.

- Sufficient English skills to complete all testing without assistance of an English

language interpreter.

- Availability of a responsible caregiver who agrees to supervise administration of

study drug, monitor the patient's compliance and adverse events, and accompany the patient to all clinic visits. Exclusion Criteria:

- 1. Any significant neurologic disease other than HD.

- Severe psychotic features or other severe psychiatric problems within the last three

months which could lead to difficulty complying with the protocol.

- History of alcohol or substance abuse within the past two years (DSM IV criteria).

- Any significant systemic illness or unstable medical condition which could lead to

difficulty complying with the protocol.

- History of MI in the past year or head trauma with loss of consciousness greater than

20 minutes.

- Insulin-requiring diabetes.

- Use of any FDA approved cognitive enhancing prescription medications or

investigational drugs within 30 days.

- Use of ginkgo biloba or DHEA within four weeks prior to baseline.

- Use of narcotic analgesics within 4 weeks prior to baseline.

- Patients who, in the investigator's opinion, would not comply with study procedures.

Locations and Contacts

Jody Corey-Bloom, MD, PhD, Phone: 858-642-3470, Email: jcoreybl@vapop.ucsd.edu

University of California, San Diego, La Jolla, California 92037, United States; Recruiting
Jody Corey-Bloom, MD, PhD, Phone: 858-642-3470, Email: jcoreybl@vapop.ucsd.edu
Jody Goldstein, BA, Phone: 858-622-5854, Email: jlgoldstein@ucsd.edu
Jody Corey-Bloom, MD, PhD, Principal Investigator

University of Kansas Medical Center, Kansas City, Kansas 66160, United States; Recruiting
Richard Dubinsky, MD, MPH, Email: rdubinsky@safetyresearch.com
Janice Broyles-Gorman, Email: jbroyles-gorman@kumc.edu
Richard Dubinsky, MD, MPH, Principal Investigator

Johns Hopkins Hospital, Baltimore, Maryland 21287, United States; Recruiting
Adam Roseblatt, MD, Phone: 410-955-2398, Email: arosenb3@jhmi.edu
Nadine Yoritomo, Email: nyorito1@jhmi.edu
Adam Rosenblatt, MD, Principal Investigator

Additional Information

Last updated: March 31, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017